Can an arthritis drug tame a rare bone marrow cancer?
NCT ID NCT05467800
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests canakinumab, an anti-inflammatory drug, in 14 to 26 people with myelofibrosis, a rare bone marrow cancer that causes scarring, enlarged spleen, and fatigue. Participants receive injections every three weeks for about six months. The study checks if the drug can shrink the spleen, improve blood counts, and ease symptoms, while also monitoring side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
canakinumab (an anti-inflammatory drug given as a shot under the skin)
What this could lead to
If it works, this could point toward a new treatment option for myelofibrosis, a rare bone marrow cancer.
What could go wrong
This is a small, early-phase trial with only 14-26 participants, so results may not apply to everyone. The drug may not work or could cause side effects like infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atrium Health Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
Los Angeles, California, 90048, United States
-
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Ruttenberg Treatment Center
New York, New York, 10029, United States
-
The University of Kansas Cancer Center-Westwood
Westwood, Kansas, 66205, United States
-
Wake Forest Baptist Health Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157, United States